Medtronic (MDT) Cash & Equivalents (2013 - 2026)

Medtronic has disclosed Cash & Equivalents across 14 years of filings, most recently posting $1.1 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.1 billion, down 7.5% year-over-year; the trailing twelve-month figure through Jan 2026 was $1.1 billion (down 7.5% YoY), and the FY2025 annual result was $2.2 billion, up 72.74% from the prior year.
• Cash & Equivalents came in at $1.1 billion for Q1 2026 at Medtronic, down from $1.3 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 billion in Q4 2022 to a low of $1.1 billion in Q1 2026.
• The 5-year median for Cash & Equivalents is $1.4 billion (2024), against an average of $2.1 billion.
• Across the five-year window, Cash & Equivalents plunged 72.85% in 2023 and jumped 72.74% in 2025, its largest moves.
• Medtronic's Cash & Equivalents stood at $4.8 billion in 2022, then slumped by 72.85% to $1.3 billion in 2023, then increased by 6.33% to $1.4 billion in 2024, then retreated by 8.03% to $1.3 billion in 2025, then declined by 10.53% to $1.1 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.1 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.